SIRT in 2025.
Chemotherapy
HCC
Immunotherapy
Locoregional treatment
SIRT
TARE
TKI
Yttrium-90
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
14
02
2022
accepted:
12
07
2022
pubmed:
9
8
2022
medline:
4
11
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Selective internal radiation therapy represents an endovascular treatment option for patients with primary liver malignancies, in different clinical stages. Potential applications of this treatment are in early-stage hepatocellular carcinoma, as a curative option, or in combination with systemic treatments in intermediate and advanced-stages. This review, based on existing literature and ongoing trials, will focus on the future of this treatment in patients with hepatocellular carcinoma, in combination with systemic treatments, or with the use of new devices and technological developments; it will also describe new potential future indications and structural and organizational perspectives.
Identifiants
pubmed: 35941244
doi: 10.1007/s00270-022-03228-6
pii: 10.1007/s00270-022-03228-6
pmc: PMC9360734
doi:
Substances chimiques
Yttrium Radioisotopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1622-1633Informations de copyright
© 2022. The Author(s).
Références
Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826–37. https://doi.org/10.1002/hep.26014 .
doi: 10.1002/hep.26014
pubmed: 22911442
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2021;S0168–8278(21):02223–6. https://doi.org/10.1016/j.jhep.2021.11.018 .
doi: 10.1016/j.jhep.2021.11.018
Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, Patel RS, Nowakowski FS, Fischman AM, Kim E. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma Up to 3 cm: a propensity score matching study. Radiology. 2017;283(3):895–905. https://doi.org/10.1148/radiol.2016160718 .
doi: 10.1148/radiol.2016160718
pubmed: 27930089
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235 .
doi: 10.1093/annonc/mdw235
pubmed: 27380959
Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J hepatol. 2015;62(3):617–24.
doi: 10.1016/j.jhep.2014.10.037
pubmed: 25450706
Heil J, Schadde E. Simultaneous portal and hepatic vein embolization before major liver resection. Langenbecks Arch Surg. 2021;406(5):1295–305. https://doi.org/10.1007/s00423-020-01960-6 .
doi: 10.1007/s00423-020-01960-6
pubmed: 32839889
de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol. 2009;16(2):423–30. https://doi.org/10.1245/s10434-008-0222-6 .
doi: 10.1245/s10434-008-0222-6
pubmed: 19050974
Hayashi S, Baba Y, Ueno K, Nakajo M, Kubo F, Ueno S, Aikou T, Komokata T, Nakamura N, Sakata R. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol. 2007;48(7):721–7. https://doi.org/10.1080/02841850701424514 .
doi: 10.1080/02841850701424514
pubmed: 17729001
Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36. https://doi.org/10.1016/j.jhep.2013.06.015 .
doi: 10.1016/j.jhep.2013.06.015
pubmed: 23811303
pmcid: 5085290
Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E, Boucher E. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20(8):2518–25. https://doi.org/10.1245/s10434-013-2906-9 .
doi: 10.1245/s10434-013-2906-9
pubmed: 23494107
Cucchetti A, Cappelli A, Ercolani G, Mosconi C, Cescon M, Golfieri R, Pinna AD. Selective internal radiation therapy (SIRT) as conversion therapy for unresectable primary liver malignancies. Liver Cancer. 2016;5(4):303–11. https://doi.org/10.1159/000449341 .
doi: 10.1159/000449341
pubmed: 27781202
pmcid: 5075901
Fernández-Ros N, Silva N, Bilbao JI, Iñarrairaegui M, Benito A, D’Avola D, Rodriguez M, Rotellar F, Pardo F, Sangro B. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. HPB (Oxford). 2014;16(3):243–9. https://doi.org/10.1111/hpb.12095 .
doi: 10.1111/hpb.12095
Taylor AC, Maddirela D, White SB. Role of radioembolization for biliary tract and primary liver cancer. Surg Oncol Clin N Am. 2019;28(4):731–43. https://doi.org/10.1016/j.soc.2019.07.001 .
doi: 10.1016/j.soc.2019.07.001
pubmed: 31472916
Theysohn JM, Ertle J, Müller S, Schlaak JF, Nensa F, Sipilae S, Bockisch A, Lauenstein TC. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol. 2014;69(2):172–8. https://doi.org/10.1016/j.crad.2013.09.009 .
doi: 10.1016/j.crad.2013.09.009
pubmed: 24209871
Birgin E, Rasbach E, Seyfried S, Rathmann N, Diehl SJ, Schoenberg SO, Reissfelder C, Rahbari NN. Contralateral liver hypertrophy and oncological outcome following radioembolization with 90Y-microspheres: a systematic review. Cancers (Basel). 2020;12(2):294. https://doi.org/10.3390/cancers12020294 .
doi: 10.3390/cancers12020294
pmcid: 7072354
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 radioembolization for the treatment of solitary. Unresectable HCC: LEGACY Study Hepatology. 2021;74(5):2342–52. https://doi.org/10.1002/hep.31819 .
doi: 10.1002/hep.31819
pubmed: 33739462
Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16(6):1587–96. https://doi.org/10.1245/s10434-009-0454-0 .
doi: 10.1245/s10434-009-0454-0
pubmed: 19357924
Liebl M, Pedersoli F, Zimmermann M, Schulze-Hagen M, Truhn D, Sieben P, von Stillfried S, Tschinaev A, Heinzel A, Kuhl CK, Bruners P, Isfort P. Induction of contralateral hepatic hypertrophy by unilobar yttrium-90 transarterial radioembolization versus portal vein embolization: an animal study. J Vasc Interv Radiol. 2021;32(6):836-842.e2. https://doi.org/10.1016/j.jvir.2021.01.281 .
doi: 10.1016/j.jvir.2021.01.281
pubmed: 33689835
Kutlu R, Karatoprak S. Radioembolization for hepatocellular carcinoma in downstaging and bridging for liver transplantation. J Gastrointest Cancer. 2020;51(4):1157–64. https://doi.org/10.1007/s12029-020-00492-y .
doi: 10.1007/s12029-020-00492-y
pubmed: 32880041
Samim M, Lam MGEH. Safety and efficacy of Y-90 radioembolization after prior major hepatic resection: dosimetric consideration. Cardiovasc Intervent Radiol. 2017;40(8):1293–4. https://doi.org/10.1007/s00270-017-1704-3 .
doi: 10.1007/s00270-017-1704-3
pubmed: 28550511
Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of hepatocellular carcinoma response after 90Y RADIOEMBOLIZATION. AJR Am J Roentgenol. 2017;209(5):W263–76. https://doi.org/10.2214/AJR.17.17993 .
doi: 10.2214/AJR.17.17993
pubmed: 29072955
Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, Lenoir L, Boudjema K, Ugen T, Brun V, Mesbah H, Haumont LA, Loyer P, Garin E. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392–401. https://doi.org/10.1007/s00259-017-3845-7 .
doi: 10.1007/s00259-017-3845-7
pubmed: 29177870
Fernandez-Ros N, Iñarrairaegui M, Paramo JA, Berasain C, Avila MA, Chopitea A, Varo N, Sarobe P, Bilbao JI, Dominguez I, D’Avola D, Herrero JI, Quiroga J, Sangro B. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int. 2015;35(5):1590–6. https://doi.org/10.1111/liv.12592 .
doi: 10.1111/liv.12592
pubmed: 24836705
Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, Salem R. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580–3. https://doi.org/10.1007/s00259-020-04976-8 .
doi: 10.1007/s00259-020-04976-8
pubmed: 32749512
Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of use of Y90 as a bridge to liver resection and transplantation in hepatocellular carcinoma. J Gastrointest Surg. 2021;25(10):2690–9. https://doi.org/10.1007/s11605-021-05095-x .
doi: 10.1007/s11605-021-05095-x
pubmed: 34345997
Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med. 2019;49(3):237–43. https://doi.org/10.1053/j.semnuclmed.2019.01.008 .
doi: 10.1053/j.semnuclmed.2019.01.008
pubmed: 30954190
Depalo T, Boni G, Ghinolfi D, Bozzi E, Cervelli R, Catalano G, Volterrani D, Bargellini I. Potential benefits of holmium-166 radioembolization as a neoadjuvant treatment of intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2021;44(2):345–7. https://doi.org/10.1007/s00270-020-02607-1 .
doi: 10.1007/s00270-020-02607-1
pubmed: 33090248
Riby D, Mazzotta AD, Bergeat D, Verdure L, Sulpice L, Bourien H, Lièvre A, Rolland Y, Garin E, Boudjema K, Edeline J. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27(10):3729–37. https://doi.org/10.1245/s10434-020-08486-7 .
doi: 10.1245/s10434-020-08486-7
pubmed: 32472411
Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, Ayav A, Campillo-Gimenez B, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Boucher E, Garin E. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51–9. https://doi.org/10.1001/jamaoncol.2019.3702 .
doi: 10.1001/jamaoncol.2019.3702
pubmed: 31670746
Tabone M, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol. 2020;11(1):84–90. https://doi.org/10.21037/jgo.2019.06.01 .
doi: 10.21037/jgo.2019.06.01
pubmed: 32175109
pmcid: 7052761
Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB, Humar A, Geller DA, Marsh JW, Tsung A. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013;24(11):1632–8. https://doi.org/10.1016/j.jvir.2013.07.026 .
doi: 10.1016/j.jvir.2013.07.026
pubmed: 24160821
Bilbao JL, Iezzi R, Goldberg SN, Sami A, Akhan O, Giuliante F, Pompili M, Crocetti L, Malagari K, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. The ten commandments of hepatic radioembolization: expert discussion and report from mediterranean interventional oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci. 2017;21(18):4014–21.
pubmed: 29028102
Shannon AM, Williams KJ. Antiangiogenics and radiotherapy. J Pharm Pharmacol. 2008;60(8):1029–36. https://doi.org/10.1211/jpp.60.8.0009 .
doi: 10.1211/jpp.60.8.0009
pubmed: 18644195
Marques FG, Poli E, Malaquias J, Carvalho T, Portêlo A, Ramires A, Aldeia F, Ribeiro RM, Vitorino E, Diegues I, Costa L. Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues. Radiother Oncol. 2019;141:256–61.
doi: 10.1016/j.radonc.2019.06.035
Kanthou C, Tozer G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br J Radiol. 2019;92(1093):20180405. https://doi.org/10.1259/bjr.20180405 .
doi: 10.1259/bjr.20180405
pubmed: 30160184
Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; A therapeutic triad for cancer? Front Immunol. 2019;14(9):3107. https://doi.org/10.3389/fimmu.2018.03107 .
doi: 10.3389/fimmu.2018.03107
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, Cosme A, de Oliveira A, Santoro J-LR, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857 .
doi: 10.1056/NEJMoa0708857
pubmed: 18650514
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1 .
doi: 10.1016/S0140-6736(18)30207-1
pubmed: 29433850
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
doi: 10.1016/S0140-6736(16)32453-9
pubmed: 27932229
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002 .
doi: 10.1056/NEJMoa1717002
pubmed: 29972759
pmcid: 7523244
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96.
doi: 10.1016/S1470-2045(18)30937-9
pubmed: 30665869
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul Jean-L, Schirmacher P, Vilgrain V. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019 .
doi: 10.1016/j.jhep.2018.03.019
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki J-P, Tasu J-P, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz J-F, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul J-L, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36. https://doi.org/10.1016/S1470-2045(17)30683-6 .
doi: 10.1016/S1470-2045(17)30683-6
pubmed: 29107679
Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol. 2020;16(1):4315–25. https://doi.org/10.2217/fon-2019-0658 .
doi: 10.2217/fon-2019-0658
pubmed: 31797680
Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V. SARAH Trial Group Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology. 2020;296(3):673–84.
doi: 10.1148/radiol.2020191606
pubmed: 32602828
Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Janus Ong S, Choo P, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han H-S, Bae S-H, Yoon H-K, Lee R-C, Hung C-F, Peng C-Y, Liang P-C, Bartlett A, Kok KYY, Thng C-H, Low AS-C, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21. https://doi.org/10.1200/JCO.2017.76.0892 .
doi: 10.1200/JCO.2017.76.0892
pubmed: 29498924
Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164–74. https://doi.org/10.1016/j.jhep.2019.08.006 .
doi: 10.1016/j.jhep.2019.08.006
pubmed: 31421157
Ricke J, Schinner R, Seidensticker M, Gasbarrini A, van Delden OM, Amthauer H, Peynircioglu B, Bargellini I, Iezzi R, De Toni EN, Malfertheiner P, Pech M, Sangro B. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. J Hepatol. 2021;75(6):1387–96. https://doi.org/10.1016/j.jhep.2021.07.037 .
doi: 10.1016/j.jhep.2021.07.037
pubmed: 34454995
Öcal O, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Iezzi R, Benito A, Schütte K, Gasbarrini A, Seidensticker R, Wildgruber M, Pech M, Malfertheiner P, Ricke J, Seidensticker M. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. Eur Radiol. 2022;32(2):1320–9. https://doi.org/10.1007/s00330-021-08218-9 .
doi: 10.1007/s00330-021-08218-9
pubmed: 34467453
Schütte K, Schinner R, Fabritius MP, Möller M, Kuhl C, Iezzi R, Öcal O, Pech M, Peynircioglu B, Seidensticker M, Sharma R, Palmer D, Bronowicki JP, Reimer P, Malfertheiner P, Ricke J. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC trial. Liver Cancer. 2020;9(6):771–86. https://doi.org/10.1159/000510798 .
doi: 10.1159/000510798
pubmed: 33442545
pmcid: 7768116
Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13(3):414–20. https://doi.org/10.3748/wjg.v13.i3.414 .
doi: 10.3748/wjg.v13.i3.414
pubmed: 17230611
pmcid: 4065897
Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, Pereira H, Gandhi M, Malfertheiner P, Chow PKH, Vilgrain V, Ricke J, Leandro G. NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radiation therapy with 90Y resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61(12):1736–42. https://doi.org/10.2967/jnumed.120.242933 .
doi: 10.2967/jnumed.120.242933
pubmed: 32358087
Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after 90Y-radioembolization with glass microspheres using 90Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–61. https://doi.org/10.1016/j.ijrobp.2018.05.062 .
doi: 10.1016/j.ijrobp.2018.05.062
pubmed: 30191875
Lewandowski RJ, Salem R. Radioembolisation with personalised dosimetry: improving outcomes for patients with advanced hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2021;6(1):2–3. https://doi.org/10.1016/S2468-1253(20)30306-X .
doi: 10.1016/S2468-1253(20)30306-X
pubmed: 33166498
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A prospective phase II study of safety and efficacy of sorafenib followed by 90Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;9(8):1129–45. https://doi.org/10.2147/JHC.S318865 .
doi: 10.2147/JHC.S318865
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;24(16):223–49. https://doi.org/10.1146/annurev-pathol-042020-042741 .
doi: 10.1146/annurev-pathol-042020-042741
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77. https://doi.org/10.1038/nri2326 .
doi: 10.1038/nri2326
pubmed: 18500231
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. In: FDA. 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma . Accessed 31 Jan 2022.
FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. In: FDA. 2019. https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma . Accessed 1 Feb 2022.
FDA Approves Atezolizumab Plus Bevacizumab for Liver Cancer. In: National Cancer Institute. 2020. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-atezolizumab-bevacizumab-liver-cancer . Accessed 1 Feb 2022.
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. In: Journal of Clinical Oncology. https://ascopubs.org/doi/abs/ https://doi.org/10.1200/JCO.2022.40.4_suppl.379 . Accessed 31 Jan 2022.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Derek-Zhen X, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng A-L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745 .
doi: 10.1056/NEJMoa1915745
pubmed: 32402160
Daniel Grass G, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Current Problems in Cancer. 2016;40(1):10–24. https://doi.org/10.1016/j.currproblcancer.2015.10.003 .
doi: 10.1016/j.currproblcancer.2015.10.003
pubmed: 26612692
Rodriguez-Ruiz ME, Rodriguez I, Leaman O, López-Campos F, Montero A, Conde AJ, Aristu JJ, Lara P, Calvo FM, Melero I. Immune mechanisms mediating abscopal effects in radioimmunotherapy. Pharmacol Ther. 2019;196:195–203. https://doi.org/10.1016/j.pharmthera.2018.12.002 .
doi: 10.1016/j.pharmthera.2018.12.002
pubmed: 30529041
Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int. 2013;2013: 658126. https://doi.org/10.1155/2013/658126 .
doi: 10.1155/2013/658126
pubmed: 24324970
pmcid: 3845488
Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol. 2019;25(20):2416–29. https://doi.org/10.3748/wjg.v25.i20.2416 .
doi: 10.3748/wjg.v25.i20.2416
pubmed: 31171886
pmcid: 6543238
Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: a comprehensive review and latest developments. Cancers (Basel). 2021;13(4):678. https://doi.org/10.3390/cancers13040678 .
doi: 10.3390/cancers13040678
pubmed: 33567530
pmcid: 7915834
Mortezaee K, Najafi M. Immune system in cancer radiotherapy: resistance mechanisms and therapy perspectives. Crit Rev Oncol Hematol. 2021;157: 103180. https://doi.org/10.1016/j.critrevonc.2020.103180 .
doi: 10.1016/j.critrevonc.2020.103180
pubmed: 33264717
Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, Chung A, Lo RHG, Ng D, Filarca RLF, Albani S, Chow PKH. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335–46. https://doi.org/10.1136/gutjnl-2017-315485 .
doi: 10.1136/gutjnl-2017-315485
pubmed: 29440463
Estrade F, Lescure C, Muzellec L, Pedrono M, Palard X, Pracht M, Le Sourd S, Rolland Y, Uguen T, Garin E, Edeline J. Lymphocytes and neutrophil-to-lymphocyte ratio variations after selective internal radiation treatment for HCC: a retrospective cohort study. Cardiovasc Intervent Radiol. 2020;43(8):1175–81. https://doi.org/10.1007/s00270-020-02467-9 .
doi: 10.1007/s00270-020-02467-9
pubmed: 32342156
Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, Park JS, Dagher NN, Taslakian B, Hickey RM. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31(1):25–34. https://doi.org/10.1016/j.jvir.2019.05.023 .
doi: 10.1016/j.jvir.2019.05.023
pubmed: 31422022
Marinelli B, Cedillo M, Pasik SD, Charles D, Murthy S, Patel RS, Fischman A, Ranade M, Bishay V, Nowakowski S, Sung M, Marron T, Lookstein R, Schwartz M, Kim E. Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients. J Vasc Interv Radiol. 2020;31(11):1729-1738.e1. https://doi.org/10.1016/j.jvir.2020.07.009 .
doi: 10.1016/j.jvir.2020.07.009
pubmed: 33012649
Fenton SE, Kircher SM, Mulcahy MF, Mulcahy MF, Mahalingam D, Salem R, Lewandowski R, Kulik L, Benson AB, Kalyan A. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer. JCO. 2021;39:e16183–e16183. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16183 .
doi: 10.1200/JCO.2021.39.15_suppl.e16183
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209–678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1025–35. https://doi.org/10.1016/S2468-1253(21)00305-8 .
doi: 10.1016/S2468-1253(21)00305-8
pubmed: 34695377
Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs. 2022;9:1–14. https://doi.org/10.1080/13543784.2022.2033208 .
doi: 10.1080/13543784.2022.2033208
Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641–57. https://doi.org/10.1148/radiol.11081489 .
doi: 10.1148/radiol.11081489
pubmed: 21602502
pmcid: 3400295
Chakravarty R, Dash A, Pillai MR. Availability of yttrium-90 from strontium-90: a nuclear medicine perspective. Cancer Biother Radiopharm. 2012;27(10):621–41. https://doi.org/10.1089/cbr.2012.1285 .
doi: 10.1089/cbr.2012.1285
pubmed: 23009585
Radosa CG, Radosa JC, Grosche-Schlee S, Zöphel K, Plodeck V, Kühn JP, Kotzerke J, Hoffmann RT. Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol. 2019;42(3):405–12. https://doi.org/10.1007/s00270-018-2133-7 .
doi: 10.1007/s00270-018-2133-7
pubmed: 30603976
Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13(10):1025–34. https://doi.org/10.1016/S1470-2045(12)70334-0.Erratum.In:LancetOncol.2012Nov;13(11):e464 .
doi: 10.1016/S1470-2045(12)70334-0.Erratum.In:LancetOncol.2012Nov;13(11):e464
pubmed: 22920685
van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat AJAT, de Jong HWAM, Elias SG, Lam MGEH. Dose-effect relationships of 166Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272–9. https://doi.org/10.2967/jnumed.120.243832 .
doi: 10.2967/jnumed.120.243832
pubmed: 32591491
Tan HY, Wong YH, Kasbollah A, Md Shah MN, Abdullah BJJ, Perkins AC, Yeong CH. Development of neutron-activated samarium-153-loaded polystyrene microspheres as a potential theranostic agent for hepatic radioembolization. Nucl Med Commun. 2022;43(4):410–22. https://doi.org/10.1097/MNM.0000000000001529 .
doi: 10.1097/MNM.0000000000001529
pubmed: 35045548
Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34(7):1031–6.
pubmed: 7686217
Hashikin NA, Yeong CH, Abdullah BJ, Ng KH, Chung LY, Dahalan R, Perkins AC. Neutron activated samarium-153 microparticles for transarterial radioembolization of liver tumour with post-procedure imaging capabilities. PLoS ONE. 2015;10(9): e0138106. https://doi.org/10.1371/journal.pone.0138106 .
doi: 10.1371/journal.pone.0138106
pubmed: 26382059
pmcid: 4575131
Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Yeong CH. Preparation and in vitro evaluation of neutron-activated, theranostic samarium-153-labeled microspheres for transarterial radioembolization of hepatocellular carcinoma and liver metastasis. Pharmaceutics. 2019;11(11):596. https://doi.org/10.3390/pharmaceutics11110596 .
doi: 10.3390/pharmaceutics11110596
pmcid: 6920762
Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Acharya RU, Yeong CH. Neutron-activated biodegradable samarium-153 acetylacetonate-poly-L-lactic acid microspheres for intraarterial radioembolization of hepatic tumors. World J Exp Med. 2020;10(2):10–25. https://doi.org/10.5493/wjem.v10.i2.10 .
doi: 10.5493/wjem.v10.i2.10
pubmed: 32266125
pmcid: 7117964
Klaassen NJM, Arntz MJ, Gil Arranja A, Roosen J, Nijsen JFW. The various therapeutic applications of the medical isotope holmium-166: a narrative review. EJNMMI Radiopharm Chem. 2019;4(1):19. https://doi.org/10.1186/s41181-019-0066-3 .
doi: 10.1186/s41181-019-0066-3
pubmed: 31659560
pmcid: 6682843
Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. Front Med (Lausanne). 2019;14(6):132. https://doi.org/10.3389/fmed.2019.00132 .
doi: 10.3389/fmed.2019.00132
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Denis Lacombe J, Cairncross G, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330 .
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60. https://doi.org/10.1038/nature05236 .
doi: 10.1038/nature05236
pubmed: 17051156
Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas a joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer. 1983;52(6):997–1007.
doi: 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2
pubmed: 6349785
Lawrence YR, Wang M, Dicker AP, Andrews D, Curran WJ Jr, Michalski JM, Souhami L, Yung WK, Mehta M. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer. 2011;104(9):1365–71. https://doi.org/10.1038/bjc.2011.123 .
doi: 10.1038/bjc.2011.123
pubmed: 21487410
pmcid: 3101937
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63. https://doi.org/10.1016/j.ijrobp.2004.09.004 .
doi: 10.1016/j.ijrobp.2004.09.004
pubmed: 15590187
Pasciak AS, Manupipatpong S, Hui FK, Gainsburg L, Krimins R, Zink MC, Brayton CF, Morris M, Sage J, Donahue DR, Dreher MR, Kraitchman DL, Weiss CR. Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model. EJNMMI Res. 2020;10(1):96. https://doi.org/10.1186/s13550-020-00679-1.Erratum.In:EJNMMIRes.2020Sep10;10(1):104 .
doi: 10.1186/s13550-020-00679-1.Erratum.In:EJNMMIRes.2020Sep10;10(1):104
pubmed: 32804262
pmcid: 7431501
van Es RJ, Nijsen JF, van het Schip AD, Dullens HF, Slootweg PJ, Koole R. Intra-arterial embolization of head-and-neck cancer with radioactive holmium-166 poly(L-lactic acid) microspheres: an experimental study in rabbits. Int J Oral Maxillofac Surg. 2001;30(5):407–13. https://doi.org/10.1054/ijom.2001.0129 .
doi: 10.1054/ijom.2001.0129
pubmed: 11720043
Mouli SK, Raiter S, Harris K, Mylarapu A, Burks M, Li W, Gordon AC, Khan A, Matsumoto M, Bailey KL, Pasciak AS, Manupipatpong S, Weiss CR, Casalino D, Miller FH, Gates VL, Hohlastos E, Lewandowski RJ, Kim DH, Dreher MR, Salem R. Yttrium-90 radioembolization to the prostate gland: proof of concept in a canine model and clinical translation. J Vasc Interv Radiol. 2021;32(8):1103-1112.e12. https://doi.org/10.1016/j.jvir.2021.01.282 .
doi: 10.1016/j.jvir.2021.01.282
pubmed: 33839262
Hickey RM, Maslowski JM, Aaltonen ET, Horn JC, Patel A, Sista AK, Gross JS. Yttrium-90 radioembolization in the office-based lab. J Vasc Interv Radiol. 2020;31(9):1442–8. https://doi.org/10.1016/j.jvir.2020.05.002 .
doi: 10.1016/j.jvir.2020.05.002
pubmed: 32800662
Pöpperl G, Helmberger T, Münzing W, Schmid R, Jacobs TF, Tatsch K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005;20(2):200–8. https://doi.org/10.1089/cbr.2005.20.200 .
doi: 10.1089/cbr.2005.20.200
pubmed: 15869456
Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol. 2007;17(5):1320–30. https://doi.org/10.1007/s00330-006-0508-7 .
doi: 10.1007/s00330-006-0508-7
pubmed: 17149621
Mancini R, Carpanese L, Sciuto R, Pizzi G, Golfieri R, Giampalma L, Cappelli A, Galaverni MC, Blotta A, Fiore F, Izzo F, Lastoria S, Mastro A, Di Marzo M, Cagol PP, Gasparini D, Geatti O, Bacchetti S, Pasqual E, Zeuli M, Paoletti G, Garufi C, Cosimelli M. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable colorectal liver metastases refractory to iv chemotherapy preliminary results on toxicity and response rates. In Vivo. 2006;20(6A):711–4.
pubmed: 17203751
Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994;35(10):1637–44.
pubmed: 7931662
Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S, Nemcek AA, Vogelzang R, Salem R. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (therasphere®): assessment of hepatic arterial embolization. CardioVasc Intervent Radiol. 2006;29(4):522–9. https://doi.org/10.1007/s00270-005-0171-4 .
doi: 10.1007/s00270-005-0171-4
pubmed: 16729228
Ogawa F, Mino-Kenudson M, Shimizu M, Ligato S, Lauwers GY. Gastroduodenitis associated with yttrium 90-microsphere selective internal radiation: an iatrogenic complication in need of recognition. Arch Pathol Lab Med. 2008;132(11):1734–8. https://doi.org/10.5858/132.11.1734 .
doi: 10.5858/132.11.1734
pubmed: 18976008
Crowder CD, Grabowski C, Inampudi S, Sielaff T, Sherman CA, Batts KP. Selective internal radiation therapy-induced extrahepatic injury: an emerging cause of iatrogenic organ damage. Am J Surg Pathol. 2009;33(7):963–75. https://doi.org/10.1097/PAS.0b013e31817ed787 .
doi: 10.1097/PAS.0b013e31817ed787
pubmed: 18852678
Stubbs RS, O’Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg. 2006;76(8):696–703. https://doi.org/10.1111/j.1445-2197.2006.03834.x .
doi: 10.1111/j.1445-2197.2006.03834.x
pubmed: 16916386
Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum. 1979;22(6):371–5. https://doi.org/10.1007/BF02586901 .
doi: 10.1007/BF02586901
pubmed: 498890
Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33(4):919–24. https://doi.org/10.1016/0360-3016(95)00039-3 .
doi: 10.1016/0360-3016(95)00039-3
pubmed: 7591903
Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol. 2014;25(2):266–70. https://doi.org/10.1016/j.jvir.2013.11.005 .
doi: 10.1016/j.jvir.2013.11.005
pubmed: 24332243
Aberle S, Kenkel D, Becker AS, Puippe G, Burger I, Schaefer N, Pfammatter T. Outpatient yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiol Med. 2020;125(10):971–80. https://doi.org/10.1007/s11547-020-01180-4 .
doi: 10.1007/s11547-020-01180-4
pubmed: 32270335
Iezzi R, Pompili M, Posa A, Annicchiarico E, Garcovich M, Merlino B, Rodolfino E, Di Noia V, Basso M, Cassano A, Barone C, Gasbarrini A, Manfredi R, Colosimo C. Transradial versus transfemoral access for hepatic chemoembolization: intrapatient prospective single-center study. J Vasc Interv Radiol. 2017;28(9):1234–9. https://doi.org/10.1016/j.jvir.2017.06.022 .
doi: 10.1016/j.jvir.2017.06.022
pubmed: 28757286
Iezzi R, Posa A, Bilhim T, Guimaraes M. Most common misconceptions about transradial approach in interventional radiology: results from an international survey. Diagn Interv Radiol. 2021;27(5):649–53. https://doi.org/10.5152/dir.2021.20256 .
doi: 10.5152/dir.2021.20256
pubmed: 34318753
pmcid: 8480943
Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, Thornburg B, Marshall K, Salzig K, Williams M, Del Castillo C, Ganger D, Hohlastos E, Baker T, Lewandowski RJ, Salem R. Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43(13):2353–9. https://doi.org/10.1007/s00259-016-3438-x .
doi: 10.1007/s00259-016-3438-x
pubmed: 27315059
Li MD, Chu KF, DePietro A, Wu V, Wehrenberg-Klee E, Zurkiya O, Liu RW, Ganguli S. Same-day yttrium-90 radioembolization: feasibility with resin microspheres. J Vasc Interv Radiol. 2019;30(3):314–9. https://doi.org/10.1016/j.jvir.2018.10.016 .
doi: 10.1016/j.jvir.2018.10.016
pubmed: 30819470
Calvo A, Tabone M, Carbonatto P, Richetta E, Pellerito R. Radioembolization in a single session using 90-yttrium resin microspheres. J Vasc Interv Radiol. 2019;30(10):1648–9. https://doi.org/10.1016/j.jvir.2019.06.023 .
doi: 10.1016/j.jvir.2019.06.023
pubmed: 31514998
Gabr A, Ali R, Al Asadi A, Mora R, Mouli S, Riaz A, Salem R, Lewandowski RJ. Technical aspects and practical approach toward same-day Y90 radioembolization in the management of hepatocellular carcinoma. Tech Vasc Interv Radiol. 2019;22(2):93–9. https://doi.org/10.1053/j.tvir.2019.02.009 .
doi: 10.1053/j.tvir.2019.02.009
pubmed: 31079717
Elsayed M, Loya M, Galt J, Schuster DM, Bercu ZL, Newsome J, Brandon D, Benenati S, Behbahani K, Duszak R, Sethi I, Kokabi N. Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World J Gastrointest Oncol. 2021;13(5):440–52. https://doi.org/10.4251/wjgo.v13.i5.440 .
doi: 10.4251/wjgo.v13.i5.440
pubmed: 34040704
pmcid: 8131908
Ezponda A, Rodríguez-Fraile M, Morales M, Vivas I, De La Torre M, Sangro B, Bilbao JI. Hepatic flow redistribution is feasible in patients with hepatic malignancies undergoing same-day work-up angiography and yttrium-90 microsphere radioembolization. Cardiovasc Intervent Radiol. 2020;43(7):987–95. https://doi.org/10.1007/s00270-019-02371-x .
doi: 10.1007/s00270-019-02371-x
pubmed: 31848672
Keane G, Lam M, de Jong H. Beyond the MAA-Y90 paradigm: the evolution of radioembolization dosimetry approaches and scout particles. Semin Intervent Radiol. 2021;38(5):542–53. https://doi.org/10.1055/s-0041-1736660 .
doi: 10.1055/s-0041-1736660
pubmed: 34853500
Smits MLJ, Dassen MG, Prince JF, Braat AJAT, Beijst C, Bruijnen RCG, de Jong HWAM, Lam MGEH. The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806. https://doi.org/10.1007/s00259-019-04460-y .
doi: 10.1007/s00259-019-04460-y
pubmed: 31399801
Elschot M, Nijsen JF, Lam MG, Smits ML, Prince JF, Viergever MA, van den Bosch MA, Zonnenberg BA, de Jong HW. (
doi: 10.1007/s00259-014-2784-9
pubmed: 24819055
Braat AJAT, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. Eur Radiol. 2018;28(3):920–8. https://doi.org/10.1007/s00330-017-4998-2 .
doi: 10.1007/s00330-017-4998-2
pubmed: 28786008
Bakker RC, Bastiaannet R, van Nimwegen SA, Barten-van Rijbroek AD, Van Es RJJ, Rosenberg AJWP, de Jong HWAM, Lam MGEH, Nijsen JFW. Feasibility of CT quantification of intratumoural 166Ho-microspheres. Eur Radiol Exp. 2020. https://doi.org/10.1186/s41747-020-00157-2 .
doi: 10.1186/s41747-020-00157-2
van Roekel C, Harlianto NI, Braat AJAT, Prince JF, van den Hoven AF, Bruijnen RCG, Lam MGEH, Smits MLJ. Evaluation of the safety and feasibility of same-day holmium-166 -radioembolization simulation and treatment of hepatic metastases. J Vasc Interv Radiol. 2020;31(10):1593–9. https://doi.org/10.1016/j.jvir.2020.01.032 .
doi: 10.1016/j.jvir.2020.01.032
pubmed: 32861571